Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681950 | 0.89 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL9483543 | 0.83 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL434232 | 0.82 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL10961767 | 0.80 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL8716409 | 0.80 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL6840326 | 0.80 | ALDH1A1 (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL4482845 | 0.80 | GAA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| Bis(Pivaloyloxymethyl) Succinate SCHEMBL3123390 | 0.80 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL10403143 | 0.80 | POLB (0.43) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL4482847 | 0.79 | PRKCA (0.37) | PRKCABTN3A1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | claimed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | claimed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | claimed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | claimed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3932931-B1 | A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4341266-A1 | PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117460734-A | Pentacyclic derivatives as Zika virus inhibitors | 吉利德科学公司 | 2024-01-26 | — | — | CN | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4891363-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY LIMITED (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0319050-A2 | Griseolic acid derivatives, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1989-06-07 | — | — | EP | disclosed |
| EP-0318060-A2 | Griseolic acid derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0251827-A2 | New cyclic ether derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-01-07 | — | — | EP | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| EP-0214708-A2 | Griseolic acid derivatives, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | PRKCA 1291/4885BTN3A1 3116/4885ALDH1A1 4695/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | PRKCA 1291/4885BTN3A1 3116/4885ALDH1A1 4695/4885 |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | MTAP, PNP, NSUN2 | PRKCA 666/4885BTN3A1 4120/4885ALDH1A1 3254/4885 |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | ZC3HAV1, ZC3HAV1L, GDI1 | PRKCA 3776/4885BTN3A1 3334/4885ALDH1A1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.